AGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Allergan PLC's research and development for the three months ended in Dec. 2016 was $913 Mil. Its research and development for the trailing twelve months (TTM) ended in Dec. 2016 was $2,576 Mil.
This is the expense the company spent on research and development.
Allergan PLC Research & Development for the trailing twelve months (TTM) ended in Dec. 2016 was 403.1 (Mar. 2016 ) + 636.5 (Jun. 2016 ) + 622.8 (Sep. 2016 ) + 913.3 (Dec. 2016 ) = $2,576 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Allergan PLC Annual Data
|Research & Development||145||170||197||296||307||403||191||606||2,359||2,576|
Allergan PLC Quarterly Data
|Research & Development||277||237||431||455||1,261||431||403||637||623||913|